» Articles » PMID: 32857910

GSK3-ARC/Arg3.1 and GSK3-Wnt Signaling Axes Trigger Amyloid-β Accumulation and Neuroinflammation in Middle-aged Shugoshin 1 Mice

Overview
Journal Aging Cell
Specialties Cell Biology
Geriatrics
Date 2020 Aug 29
PMID 32857910
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The cerebral amyloid-β accumulation that begins in middle age is considered the critical triggering event in the pathogenesis of late-onset Alzheimer's disease (LOAD). However, the molecular mechanism remains elusive. The Shugoshin 1 (Sgo1 ) mouse model, a model for mitotic cohesinopathy-genomic instability that is observed in human AD at a higher rate, showed spontaneous accumulation of amyloid-β in the brain at old age. With the model, novel insights into the molecular mechanism of LOAD development are anticipated. In this study, the initial appearance of cerebral amyloid-β accumulation was determined as 15-18 months of age (late middle age) in the Sgo1 model. The amyloid-β accumulation was associated with unexpected GSK3α/β inactivation, Wnt signaling activation, and ARC/Arg3.1 accumulation, suggesting involvement of both the GSK3-Arc/Arg3.1 axis and the GSK3-Wnt axis. As observed in human AD brains, neuroinflammation with IFN-γ expression occurred with amyloid-β accumulation and was pronounced in the aged (24-month-old) Sgo1 model mice. AD-relevant protein panels (oxidative stress defense, mitochondrial energy metabolism, and β-oxidation and peroxisome) analysis indicated (a) early increases in Pdk1 and Phb in middle-aged Sgo1 brains, and (b) misregulations in 32 proteins among 130 proteins tested in old age. Thus, initial amyloid-β accumulation in the Sgo1 model is suggested to be triggered by GSK3 inactivation and the resulting Wnt activation and ARC/Arg3.1 accumulation. The model displayed characteristics and affected pathways similar to those of human LOAD including neuroinflammation, demonstrating its potential as a study tool for the LOAD development mechanism and for preclinical AD drug research and development.

Citing Articles

Synergistic activity of nootropic herbs as potent therapeutics for Alzheimer's disease: A cheminformatics, pharmacokinetics, and system pharmacology approach.

Don Bosco R, Selvan Christyraj J, Yesudhason B J Alzheimers Dis Rep. 2025; 8(1):1745-1762.

PMID: 40034353 PMC: 11863741. DOI: 10.1177/25424823241307019.


Brain Plasticity and Cell Competition: Immediate Early Genes Are the Focus.

Tregub P, Komleva Y, Kukla M, Averchuk A, Vetchinova A, Rozanova N Cells. 2025; 14(2).

PMID: 39851571 PMC: 11763428. DOI: 10.3390/cells14020143.


Age- and Sex-Associated Wnt Signaling Dysregulation is Exacerbated from the Early Stages of Neuropathology in an Alzheimer's Disease Model.

Colin-Martinez E, Espino-de-la-Fuente C, Arias C Neurochem Res. 2024; 49(11):3094-3104.

PMID: 39167347 PMC: 11449975. DOI: 10.1007/s11064-024-04224-7.


Mechanisms and Functions of Activity-Regulated Cytoskeleton-Associated Protein in Synaptic Plasticity.

Chen Y, Wang X, Xiao B, Luo Z, Long H Mol Neurobiol. 2023; 60(10):5738-5754.

PMID: 37338805 DOI: 10.1007/s12035-023-03442-4.


Treatment of Alzheimer's disease by combination of acupuncture and Chinese medicine based on pathophysiological mechanism: A review.

Liu Z, Guan R, Bu F, Pan L Medicine (Baltimore). 2023; 101(49):e32218.

PMID: 36626477 PMC: 9750551. DOI: 10.1097/MD.0000000000032218.


References
1.
Huang L, Chao S, Hu C . Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020; 27(1):18. PMC: 6943903. DOI: 10.1186/s12929-019-0609-7. View

2.
Butterfield D, Poon H, St Clair D, Keller J, Pierce W, Klein J . Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis. 2006; 22(2):223-32. DOI: 10.1016/j.nbd.2005.11.002. View

3.
Waltereit R, Dammermann B, Wulff P, Scafidi J, Staubli U, Kauselmann G . Arg3.1/Arc mRNA induction by Ca2+ and cAMP requires protein kinase A and mitogen-activated protein kinase/extracellular regulated kinase activation. J Neurosci. 2001; 21(15):5484-93. PMC: 6762636. View

4.
Shepherd C, Yang Y, Halliday G . Region- and Cell-specific Aneuploidy in Brain Aging and Neurodegeneration. Neuroscience. 2018; 374:326-334. DOI: 10.1016/j.neuroscience.2018.01.050. View

5.
Saito T, Saido T . Neuroinflammation in mouse models of Alzheimer's disease. Clin Exp Neuroimmunol. 2018; 9(4):211-218. PMC: 6282739. DOI: 10.1111/cen3.12475. View